Cagrilintide

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

Analysts say the once-daily small‑molecule pill could qualify for a new FDA voucher that speeds reviews to one or two months.